Rosetta acquires Wishbone

Share this article:

Rosetta, the largest independent digital marketing agency in the US, has acquired Wishbone for an undisclosed sum.

Wishbone will retain its name and management team, and will be integrated into Rosetta's overall healthcare business as a separate professionally focused group. Wishbone will continue to operate from its New York offices.

Rosetta, headquartered in Princeton, NJ, is a $131 million digital agency with a client roster spanning several markets, including healthcare, consumer products, insurance, banking and retail. The healthcare business, which is focused on the consumer side, grew by 33% to $46 million in 2009. Clients include Allergan, Amgen, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Shire and Takeda.

Wishbone's 2009 revenues were up 20% to $15 million. Current clients include Baxter, Dey, Genzyme, Novartis, Otsuka and Pfizer.

The deal, which goes into effect immediately, integrates the two agencies into a $61 million independent healthcare business.

Both agency chiefs view the deal as a strong strategic match between the two organizations.

“Rosetta and Wishbone bring highly complementary strengths to the table that will benefit our clients immediately,” said Wishbone founder and CEO Steven Michaelson. “[This] will result in a new kind of agency that's even better equipped to help clients prevail in the challenging times ahead.”

“Major changes in the healthcare industry are affecting sales and marketing,” added Kurt Holstein, Rosetta's cofounder and president, citing a decreasing reliance on face-to-face detailing and increase in digital communications with healthcare professionals. “The addition of Wishbone will allow us to deliver the services our clients need in both the current and future healthcare marketing environment.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...